Log in

NYSE:RMDResMed Stock Price, Forecast & News

$175.84
+2.86 (+1.65 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$173.74
Now: $175.84
$177.37
50-Day Range
$172.72
MA: $193.26
$205.63
52-Week Range
$108.85
Now: $175.84
$208.99
Volume829,600 shs
Average Volume725,677 shs
Market Capitalization$25.44 billion
P/E Ratio41.18
Dividend Yield0.89%
Beta0.51
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; data communications and control products, such as AirView Diagnostics, EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules; U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; and myAir, a patient engagement application that provides sleep data and a daily score based on their previous night's data, as well as offers business management software and services to medical equipment and home health providers. It markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Read More
ResMed logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.0Community Rank: 1.8Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP76115210
Phone858-836-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.96 billion
Cash Flow$6.13 per share
Book Value$17.26 per share

Profitability

Net Income$621.67 million

Miscellaneous

Employees7,240
Market Cap$25.44 billion
Next Earnings Date10/22/2020 (Estimated)
OptionableOptionable
$175.84
+2.86 (+1.65 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ResMed (NYSE:RMD) Frequently Asked Questions

How has ResMed's stock been impacted by Coronavirus (COVID-19)?

ResMed's stock was trading at $153.61 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RMD stock has increased by 14.5% and is now trading at $175.84.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ResMed?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 3 sell ratings, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for ResMed
.

When is ResMed's next earnings date?

ResMed is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for ResMed
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its quarterly earnings results on Wednesday, August, 5th. The medical equipment provider reported $1.33 EPS for the quarter, topping the Zacks' consensus estimate of $0.97 by $0.36. The medical equipment provider earned $770.30 million during the quarter, compared to analysts' expectations of $755.01 million. ResMed had a net margin of 21.02% and a return on equity of 30.34%. The firm's quarterly revenue was up 9.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.95 EPS.
View ResMed's earnings history
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Wednesday, August 5th. Investors of record on Thursday, August 20th will be given a dividend of $0.39 per share on Thursday, September 24th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date is Wednesday, August 19th.
View ResMed's dividend history
.

What price target have analysts set for RMD?

11 analysts have issued 12 month price objectives for ResMed's stock. Their forecasts range from $174.00 to $210.00. On average, they expect ResMed's stock price to reach $186.67 in the next year. This suggests a possible upside of 6.2% from the stock's current price.
View analysts' price targets for ResMed
.

Has ResMed been receiving favorable news coverage?

News headlines about RMD stock have trended negative on Thursday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ResMed earned a news impact score of -2.4 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about ResMed
.

Are investors shorting ResMed?

ResMed saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 2,150,000 shares, an increase of 54.7% from the June 15th total of 1,390,000 shares. Based on an average trading volume of 685,100 shares, the short-interest ratio is currently 3.1 days.
View ResMed's Short Interest
.

Who are some of ResMed's key competitors?

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), Adobe (ADBE), Netflix (NFLX), Visa (V), Alibaba Group (BABA), Intel (INTC), Cisco Systems (CSCO) and QUALCOMM (QCOM).

Who are ResMed's key executives?

ResMed's management team includes the following people:
  • Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 47)
  • Mr. Robert A. Douglas, Pres & COO (Age 59)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 52)
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 60)
  • Mr. James Hollingshead, Pres of Sleep Bus. (Age 56)

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (3.74%), Bank of New York Mellon Corp (0.90%), Sumitomo Mitsui Trust Holdings Inc. (0.73%), Congress Asset Management Co. MA (0.45%), American Capital Management Inc. (0.43%) and Swiss National Bank (0.40%). Company insiders that own ResMed stock include Brett Sandercock, David Pendarvis, James Hollingshead, John P Wareham, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends for ResMed
.

Which institutional investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Assenagon Asset Management S.A., Federated Hermes Inc., First Trust Advisors LP, Congress Asset Management Co. MA, Arizona State Retirement System, Goldman Sachs Group Inc., and New York State Common Retirement Fund. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, James Hollingshead, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas, and Ronald R Taylor.
View insider buying and selling activity for ResMed
.

Which institutional investors are buying ResMed stock?

RMD stock was purchased by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, CIBC Private Wealth Group LLC, Sumitomo Mitsui Trust Holdings Inc., Raymond James Financial Services Advisors Inc., Prudential Financial Inc., Bank of New York Mellon Corp, Fifth Third Bancorp, and Russell Investments Group Ltd..
View insider buying and selling activity for ResMed
.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $175.84.

How big of a company is ResMed?

ResMed has a market capitalization of $25.44 billion and generates $2.96 billion in revenue each year. The medical equipment provider earns $621.67 million in net income (profit) each year or $4.76 on an earnings per share basis. ResMed employs 7,240 workers across the globe.

What is ResMed's official website?

The official website for ResMed is www.resmed.com.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.